AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Adenylate kinase 7

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q96M32

UPID:

KAD7_HUMAN

Alternative names:

ATP-AMP transphosphorylase 7

Alternative UPACC:

Q96M32; Q8IYP6

Background:

Adenylate kinase 7, also known as ATP-AMP transphosphorylase 7, plays a crucial role in cellular energy homeostasis by catalyzing the transfer of phosphate groups between nucleoside triphosphates and monophosphates. It exhibits the highest activity towards AMP and is involved in maintaining ciliary structure and function, highlighting its importance in cellular mechanics and signaling.

Therapeutic significance:

The protein's association with Spermatogenic failure 27, a disorder characterized by defects in spermatogenesis leading to abnormal sperm flagella, underscores its potential as a target for therapeutic intervention. Understanding the role of Adenylate kinase 7 could open doors to potential therapeutic strategies for treating infertility issues related to spermatogenic defects.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.